Adrenaline or Epinephrine? Naming History of the Adrenal Gland Compound

Adrenaline vs.

epinephrine: historical naming and the science behind the split

Context and study design this narrative traces the early exploration of the adrenal (suprarenal) gland’s active constituent and the subsequent dispute over its naming.

It presents a historical sequence of experiments, publications, and commercial entanglements that culminated in the present-day usage where adrenaline and epinephrine refer to the same molecule, though the naming history reflects a blend of physiology, chemistry, and trademark interests rather than geography alone.

They attributed the active agent to the medullary portion of the gland prior to the isolation of the chemical entity.

• In the late 19th century, Oliver and Schäfer demonstrated that extracts from the suprarenal capsules produced a marked rise in blood pressure via arteriolar contraction.
• This initial work established a physiological effect before the precise chemistry and purification processes were resolved, setting the stage for subsequent debates about the active principle’s identity.

This label originated from Abel’s own identification of the compound he believed he had isolated and did not arise merely from external branding.

He reported isolating a chromogenic native substance that was not precipitable by ammonia, contrasting with Abel’s preparations.

• John Jacob Abel and Albert Cornelius Crawford sought to isolate the “blood-pressure-raising constituent of the suprarenal capsule.” In 1897 they described a crystalline product from the gland that appeared to replicate known cardiovascular effects, prompting a search for a therapeutically useful active compound.
• Abel proposed the name epinephrin for the isolated substance in 1899, aligning with a suggestion to use epinephris as the basis for naming the suprarenal active principle.
• Otto von Fürth contested Abel’s claim in 1900, arguing that the true physiologically active substance was a different entity, which he termed suprarenin.
• In response, Abel in 1901 argued that the native active principle was not precipitable by ammonia and asserted that what Fürth called suprarenin was simply the native form of epinephrin, thereby reframing the debate rather than resolving it outright.

He announced success in obtaining the basal molecule in a pure crystalline state and asserted that previous attempts had not achieved true purification.

He acknowledged Takamine’s priority, compared the Parke-Davis/Takamine material with his own crystalline preparations, and concluded that the two were identical.

His analysis supported a specific empirical formula (C9H13NO3), aligning more closely with Takamine’s characterization than with the earlier formulations proposed by Abel or Fürth.

• Jokichi Takamine emerged as the pivotal figure with a claim of isolating the active principle in a pure, stable crystalline form, naming it Adrenalin.
• Takamine emphasized the purity and stability of his crystalline product, arguing that the substance he isolated was the active principle in its unaltered form.
• Aldrich, a chemist with Parke, Davis & Co., provided independent chemical validation.

The early dispute about naming persisted in the literature, but the scientific consensus increasingly favored Adrenalin as the designation for the purified active principle.

under the name Adrenalin.

In contrast, Abel’s term epinephrin continued to circulate among many physiologists who viewed it as referring to a differently prepared or potentially less active preparation.

• With the convergence of chemical identification and regulatory validation, the case for Adrenalin as the crystalline active principle strengthened.
• Takamine’s purified crystalline product was patented and marketed commercially by Parke, Davis & Co.
• The broader dispute extended beyond science into commercial law, trademark considerations, and national preferences, transforming a simple naming choice into a battleground between physiologists and chemists, and between scientific usage and legal branding.

• The account documents that by the turn of the 20th century, the chemistry underpinning the active principle had become sufficiently settled to support the use of Adrenalin as the crystalline active principle’s name, although epinephrin and suprarenin persisted in earlier literature.
• The source acknowledges ongoing debates about purification and exact chemical identity during the period but notes that Aldrich’s comparative analysis aligned the Parke-Davis/Takamine material with Takamine’s claimed active principle, contributing to the resolution of the dominant nomenclature conflict.
• Although the narrative provides a cohesive timeline, it does not present quantitative outcomes, comparative pharmacology data, or contemporary clinical implications beyond historical context.

It notes that the weight of evidence shifted over time toward Adrenalin as the crystalline active principle but does not resolve every remaining discrepancy.

It remains focused on historical discovery, naming, and early chemist–physiologist rivalries.

• The historical account recognizes ongoing contention around the precise identity of the active principle during the purification debates, including differing empirical formulas proposed by multiple parties.
• The piece does not offer modern pharmacological data, clinical effectiveness comparisons, or outcome metrics.

• The write-up clarifies why adrenaline and epinephrine refer to the same molecule in current usage, rooted in a historical sequence of discovery, purification, and branding rather than purely geographic naming conventions.
• It highlights the interplay between scientific discovery and commercial considerations that can influence terminology, a reminder of the contextual factors that shape language in pharmacology and regulatory settings.